Robust improvement of Penumbra, Inc.’s PEN Thrombectomy business is poised to help the company grow in the upcoming quarters.

Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024. Penumbra ...

BTIG analyst Ryan Zimmerman maintained a Buy rating on Penumbra (PEN – Research Report) yesterday and set a price target of $270.00. The ...

Director Harpreet Grewal sold 167 shares of the company’s stock in a transaction on Friday, January 3rd. The stock was sold at an average price of $241.28, for a total value of $40,293.76. Following ...

A webcast of the presentation can be accessed on the "Events and Presentations" section under the "Investors" tab of the company's website at www.penumbrainc.com. The webcast will be available ...

Penumbra has shown significant operating leverage and profitability, with strong topline growth. Find out my recommendation ...

Penumbra, Inc. (NYSE:PEN – Get Free Report) has been given a consensus rating of “Moderate Buy” by the fifteen ratings firms that are currently covering the firm, Marketbeat reports.

Penumbra scored a strong price increase driven by optimism surrounding Stryker's entry into the high-growth mechanical thrombectomy (“MT”) sector with the acquisition of Inari Medical ...

Investing.com -- 在医疗技术板块的领军企业Stryker (NYSE: SYK)宣布达成最终协议，以每股80美元的现金价格收购Inari Medical, Inc. (NASDAQ: NARI)所有流通股后，Penumbra, Inc ...

Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025. Investing in large-cap ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...